SCHEMBL25751407

SCHEMBL25751407

CC(C)(C)OC(=O)NCc1nn(-c2ccc(OC(F)(F)F)cc2)c2nccc(CN3CC(O)C3)c12

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 7/20 0.57
▸ TEAD4 Q15561 6/20 0.57
▸ TEAD2 Q15562 6/20 0.57
▸ TEAD3 Q99594 6/20 0.57
▸ NR3C1 P04150 3/20 0.37
▸ F2 P00734 1/20 0.35
▸ F10 P00742 1/20 0.35
▸ LIPE Q05469 3/20 0.34
▸ ROS1 P08922 2/20 0.34
▸ ALK Q9UM73 2/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ SLC5A1 P13866 1/20 0.34
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424097 1.00 TEAD1 (0.57) TEAD1TEAD4TEAD2TEAD3NR3C1
SCHEMBL25225138 0.90 TEAD1 (0.61) TEAD1TEAD4TEAD2TEAD3NR3C1
SCHEMBL30424407 0.87 TEAD1 (0.59) TEAD1TEAD4TEAD2TEAD3NR3C1
SCHEMBL25209172 0.87 TEAD1 (0.59) TEAD1TEAD4TEAD2TEAD3NR3C1
SCHEMBL30424236 0.85 TEAD1 (0.61) TEAD1TEAD4TEAD2TEAD3NR3C1
SCHEMBL25751422 0.85 TEAD1 (0.61) TEAD1TEAD4TEAD2TEAD3NR3C1
SCHEMBL25747966 0.84 TEAD1 (0.50) TEAD1TEAD4TEAD2TEAD3NR3C1
SCHEMBL30424456 0.83 TEAD1 (0.51) TEAD1TEAD4TEAD2TEAD3NR3C1
SCHEMBL25229188 0.83 TEAD1 (0.53) TEAD1TEAD4TEAD2TEAD3NR3C1
SCHEMBL30423819 0.83 TEAD1 (0.53) TEAD1TEAD4TEAD2TEAD3NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118302411-A Therapeutic indazole compounds and methods of use thereof for the treatment of cancer 基因泰克公司 2024-07-05 — — CN disclosed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 TEAD1 282/4885TEAD4 162/4885TEAD2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback